AtriCure/$ATRC
1D1W1MYTD1Y5YMAX
Capital at risk
About AtriCure
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
- Ticker
- $ATRC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,350
- Headquarters
- Mason, United States
- Website
- www.atricure.com
AtriCure Metrics
BasicAdvanced
$2.9B
271.02
$0.21
1.25
-
Price and volume
Market cap
$2.9B
Beta
1.25
52-week high
$57.25
52-week low
$25.36
Average daily volume
859K
Financial strength
Current ratio
4.218
Quick ratio
3.025
Long term debt to equity
0.138
Total debt to equity
0.144
Interest coverage (TTM)
2.19%
Profitability
EBITDA (TTM)
33.712
Gross margin (TTM)
76.30%
Net profit margin (TTM)
1.85%
Operating margin (TTM)
2.26%
Effective tax rate (TTM)
12.75%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
1.25%
Return on equity (TTM)
2.15%
Valuation
Price to earnings (TTM)
271.02
Price to revenue (TTM)
4.837
Price to book
5.63
Price to tangible book (TTM)
12.19
Price to free cash flow (TTM)
52.873
Free cash flow yield (TTM)
1.89%
Free cash flow per share (TTM)
1.081
Growth
Revenue change (TTM)
13.94%
Earnings per share change (TTM)
-127.45%
3-year revenue growth (CAGR)
15.92%
10-year revenue growth (CAGR)
14.86%
3-year earnings per share growth (CAGR)
-29.94%
10-year earnings per share growth (CAGR)
-15.67%
What the Analysts think about AtriCure
Analyst ratings (Buy, Hold, Sell) for AtriCure stock.
Analyst projections of the future price of AtriCure stock.
Bulls say / Bears say
AtriCure’s Q1 2026 revenue of $141.2 million outpaced the $139.8 million consensus, with adjusted EBITDA of $17.1 million beating the $14.6 million forecast, underpinning the company’s reaffirmed 2026 revenue and EBITDA targets (Reuters)
In Q2 2026, AtriCure delivered $153.6 million in revenue versus $151.8 million expected and $27.3 million in adjusted EBITDA against a $19.9 million estimate, leading management to raise full-year revenue guidance to $602–$610 million and EBITDA to $85–$89 million (Reuters)
The company achieved a positive GAAP operating income of $0.5 million in Q1 2026, marking a return to operating profitability and reflecting improved cost discipline across its global operations (Reuters)
Despite robust top-line momentum, AtriCure’s full-year adjusted EPS guidance of $0.00–$0.04 falls short of the $0.07 IBES consensus, indicating potential headwinds to per-share earnings growth (Reuters)
Shares declined 6.4% in after-hours trading following the Q2 2026 results, underscoring investor skepticism over the company’s cautious outlook for the remainder of the year (Reuters)
A proposal at the May 18, 2026 annual meeting to authorize 1.5 million additional shares and expand the employee stock purchase plan by 750,000 shares raises dilution concerns for existing investors (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
AtriCure Financial Performance
Revenues and expenses
AtriCure Earnings Performance
Company profitability
Upcoming events
No upcoming events
AtriCure News
AllArticlesVideos
Funds containing AtriCure
AllUSDEURGBP
Fund name | Fund size | $ATRC weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.30% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.30% |
iShares Healthcare Innovation£DRDR | £1B | 0.30% |
iShares Ageing Population€AGED | €822M | 0.25% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.